1.	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
2.	Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: RaMM-BO 2.0, NCT01041612
3.	Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Phase: Phase IV Type: Treatment Status: Active Age: 19 to 70 Sponsor: Other Protocol IDs: SNUBH-GS-HBP2, B-0712-052-006 (local IRB), NCT01111591
4.	A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181202, NCT01525550
5.	Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDM00047339, E7059, NCT01774019
6.	Efficacy Study of EUS-guided Ethanol Lavage With Paclitaxel Injection for Cystic Tumors of the Pancreas Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 to 85 Sponsor: Other Protocol IDs: AMC0183, NCT00689715
7.	Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AAAD6491, NCT01065870
8.	Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000675485, PACT-15, 2010-019942-23, SRSI-PACT-15, EU-21040, NCT01150630
9.	Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: BorderlinePancreas, NCT01458717
10.	Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: TJ20111123, NCT01598584
11.	Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRE 2012.153, NCT01721174
12.	Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
13.	Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TASMC-07-NA-132-CTIL, NCT00486460
14.	Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000564099, IPC-BAYPAN, INCA-RECF0426, IPC-2005-006, BAYPAN, NCT00541021
15.	Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01987, RTOG 0848, U10CA021661, NCT01013649
16.	Immunotherapy Study for Surgically Resected Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0405, OBA# 0912-1013, NCT01072981
17.	Hyperthermia European Adjuvant Trial Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 115-09, 2008-004802-14, AIO-PAK-0111, NCT01077427
18.	Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NEOPAC, NCT01314027
19.	The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NNR-7, NCT01332773
20.	Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-22, 11PAN01, NCT01360853
21.	Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NCT-2008-11-03-1018, 60516908, NCT01362582
22.	Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MM-398-07-03-01, NCT01494506
23.	Multicentric Randomized Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 79 Sponsor: Other Protocol IDs: prodige/accord 24, NCT01526135
24.	A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Panc001, NCT01586611
25.	Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: PCI001, NCT01731821